Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Crizotinib (Xalkori®)

Status: Available in 2019 for NF2 in the United States and Canada

Crizotinib - Chemical Structure
Trade Name:
Chemical Compound:
CRZ, PF-2341066, PF-02341066,
PF2341066, PF-2341066, PF 2341066
Pharmaceutical Company:
Legal Status:
℞ - Prescription
Administered By:
Pill - Oral
Tumor Target:
Protein Target:
FAK1 (PTK2) Inhibitor
NF2 Trials:
Recruiting Trial: NCT02465060

Helpful Facts

  • In trials for: Breast Cancer, solid tumor cancer
  • Solubility: Soluble in DMSO, not in water. Dimethyl Sulfoxide (DMSO) is an organosulfur compound with the formula (CH3)2SO.
  • Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual mTOR Complex 1 and 2 inhibitor, mTORC1 and mTORC2)
  • Inhibitor: inhibits the membrane receptor MET and activation of the MET signaling pathway

Side Effects

  • upper respiratory infection,
  • nausea,
  • vomiting
  • stomach pain,
  • decreased appetite,
  • insomnia,
  • dizziness,
  • tired feeling,
  • diarrhea,
  • constipation,
  • rash or itching,
  • cold symptoms (stuffy nos
  • swelling in hands or feet.

Tell your doctor if you have serious side effects of Xalkori including:

  • severe dizziness, fainting, fast or pounding heartbeats;
  • vision problems such as blurred vision, increased sensitivity of your eyes to light, or seeing flashes of light or "floaters";
  • chest pain, dry cough or cough with mucus, wheezing, shortness of breath;
  • easy bruising, unusual bleeding, purple or red pinpoint spots under your skin;
  • fever, chills, body aches, flu symptoms, sores in your mouth and throat;
  • loss of appetite, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).


  1. Rx Lise. "Xalkori." Last reviewed on RxList 7/8/2019 https://www.rxlist.com/xalkori-side-effects-drug-center.htm
  2. Zhao, Yingchao, et al. "Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models." Proceedings of the National Academy of Sciences (2018): 201719966.
    Source: http://www.pnas.org/content/early/2018/02/07/1719966115 | DOI: 10.1073/pnas.1719966115
  3. Troutman, Scott, et al. "Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1." Oncotarget 7.34 (2016): 54515.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342359/ | DOI: 10.18632/oncotarget.10248
  4. National Center for Biotechnology Information. PubChem Compound Database; "CID=11626560", (accessed Jan. 12, 2018) Source: https://pubchem.ncbi.nlm.nih.gov/compound/11626560
  5. MedKoo Biosciences. "Crizotinib - MedKoo CAT#: 202222" (accessed Jan. 12, 2018) Source: http://www.medkoo.com/products/4537
  6. U.S. Food and Drug Administration. "FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer." (March 11, 2016)
    Source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm490329.htm
  7. Troutman, Scott, et al. "Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1." Oncotarget 7.34 (2016): 54515. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342359/
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021